News articles about Compugen (NASDAQ:CGEN) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Compugen earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.2152652067474 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Compugen (NASDAQ:CGEN) opened at 3.50 on Tuesday. The company has a 50-day moving average price of $3.25 and a 200 day moving average price of $3.91. The company’s market capitalization is $178.96 million. Compugen has a 1-year low of $2.60 and a 1-year high of $6.85.

Compugen (NASDAQ:CGEN) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). Compugen had a negative return on equity of 57.69% and a negative net margin of 4,425.00%. Equities research analysts anticipate that Compugen will post ($0.73) EPS for the current year.

Separately, Zacks Investment Research downgraded Compugen from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd.

ILLEGAL ACTIVITY NOTICE: This story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at

About Compugen

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Insider Buying and Selling by Quarter for Compugen (NASDAQ:CGEN)

Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.